☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

King's Fund critical of Health Minister

The King's Fund has criticised the Secretary of State for Health after her intervention in the use of the breast cancer drug Trastuzumab (Herceptin).

The Policy Position released by the King's Fund has raised two concerns about the Ministers intervention. These are:

  • that fast tracking might equate to more risk

Risk to patients may be increased by making drugs widely available on the NHS when little is known about the safety profile of the drug.

  • that local decisions are being undermined

The intervention of the Secretary of State for Health in the decisions around the use of Trastuzumab has indicated that the governemtn is willing to pre-empt the processes followed by NICE and PCTs.

The full document contains a more detailed analysis of why problems have been caused in many organisations across the NHS. Given the wide press coverage this debate is getting it is possible that clinicians will be asked about this drug by their patients. This article provides a good background to the issues that are being raised by the debate.

Action: Clinicians may wish to read this document or have a copy to hand should questions about this debate arise.

Share 'King's Fund critical of Health Minister' by emailShare 'King's Fund critical of Health Minister' on FacebookShare 'King's Fund critical of Health Minister' on TwitterShare 'King's Fund critical of Health Minister' on LinkedInShare 'King's Fund critical of Health Minister' on reddit


No Comments to “King's Fund critical of Health Minister”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.